Treatment with an FTO inhibitor was shown to increase m6A levels in GSCs that resulted in reduced GSC self-renewal and suppressed GBM progression, suggesting that targeting the m6A machinery can be a viable approach to treat GBM (Cui et al., 2017). Here, FTO is linked to glioblastoma.